Reaction
Non-Small Cell Lung Cancer Metastatic reporting signals
As of the last recalculation, Non-Small Cell Lung Cancer Metastatic appears in 849 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is CRIZOTINIB (PRR 104.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Crizotinib | 51 | 104.6 | 105.0 |
| Erlotinib Hydrochloride | 38 | 77.9 | 78.1 |
| Pemetrexed | 61 | 75.1 | 75.3 |
| Pemetrexed Disodium | 79 | 55.9 | 56.1 |
| Erlotinib | 14 | 36.0 | 36.1 |
| Osimertinib | 37 | 29.5 | 29.6 |
| Gefitinib | 10 | 27.5 | 27.5 |
| Carboplatin | 115 | 25.5 | 25.5 |
| Atezolizumab | 31 | 20.3 | 20.3 |
| Dabrafenib | 15 | 17.8 | 17.8 |
| Trametinib | 17 | 17.6 | 17.6 |
| Paclitaxel | 61 | 16.2 | 16.2 |
| Paclitaxel (Aibumin-Bound) | 47 | 14.8 | 14.8 |
| Prochlorperazine Maleate | 5 | 13.4 | 13.4 |
| Bevacizumab | 59 | 12.5 | 12.5 |
| Cetuximab | 11 | 8.7 | 8.7 |
| Ipilimumab | 12 | 6.9 | 6.9 |